Biologic biomarkers are not fully validated in allergic diseases. mHealth biomarkers represent a novel approach that was found feasible with mHealth apps. A validated combined symptom-medication score has been devised using MASK-air data. MASK-air is a Good Practice of DG Santé. The new CSMS is a validated,  real-life, digitally-enabled, patient-centred biomarker for any treatment, particularly AIT. The CSMS bridges clinical practice, randomised controlled trials (RCTs), observational studies, chamber studies, and real-world data. It was found to be applicable to different languages and cultures. There are around 20,000 users and 400,000 days in the database. Using the MASK-air database, a novel approach for assessing the treatment of rhinitis and asthma, including pharmacotherapy and immunotherapy, will be devised using the lessons learned by MASK-air combined with machine learning. The proposed TF will include  1 -A state-of-the-art review to find out the applicability of mHealth biomarkers. 2-The study of patterns of multimorbidity and co-medication on the treatment efficacy of rhinitis medications with a definition of short-term and long-term mHealth biomarkers. The MASK-air database – already analysed using classical methods – will be re analysed using machine learning in order to find novel phenotypes and novel treatment strategies including co-medication and multimorbidity. The strength of the database is that there are no missing values due to the structure of the app.  By analogy with diabetes, two types of mHealth biomarkers will be validated · Defining novel treatment strategies using a validated algorithm for clinicians in their practice and guideline developers for next-generation guidelines.

Chair: Jean Bousquet
Secretary: Mohamed Shamji